Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-62 for ACTH-dependent Cushing's syndrome
2021-006184-19Phase 2Active
- Sponsor
- Sparrow Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of clofutriben in ACTH-dependent Cushing's syndrome, Corticotropin adenoma (ACTHoma), ectopic corticotropin syndrome (ECS) and 1 more, sponsored by Sparrow Pharmaceuticals. Primary endpoint: Urinary HSD-1 ratio at Week 6 in subjects with Cushing’s disease. Started May 2022; status: active.
02
Drugs
clofutriben
03
Conditions
ACTH-dependent Cushing's syndromeCorticotropin adenoma (ACTHoma)ectopic corticotropin syndrome (ECS)Ectopic corticotropin-releasing hormone secretion (ECRH)
Beyond the preview
Go deeper on 2021-006184-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006184-19.